YOLFTbeta
Allergy Therapeutics

Allergy Therapeutics

AGY · LSE · Healthcare / Drug Manufacturers - Specialty & Generic

1.49GBX+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1.49
Open1.45
Day Range1.40 – 1.49
52-Week Range4.50 – 12.10
Volume1.49M
Market Cap300.80M
P/E (TTM)0.00
Forward P/E106.38
EPS-0.01
Dividend Yield0.00%
Beta0.83
50-Day Avg5.19
200-Day Avg8.71

About

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Manuel Llobet
  • Employees584
  • HeadquartersDominion Way, Worthing, United Kingdom, BN14 8SA, UK
  • Websitehttps://www.allergytherapeutics.com

Leadership

  • Mr. Manuel LlobetCEO & Executive Director · b. 1965
  • Dr. Shaun Antony FurlongCFO & Executive Director · b. 1976
  • Mr. Helge Weiner-TrapnessChief Strategy Officer & Executive Chairman · b. 1963
  • Dr. Murray SkinnerChief Scientific Officer
  • Ms. Sue BakerHead of Human Resources
  • Simon PiggottHead of Clinical Science
  • Mr. Alan BullimoreHead of Communication & Market Development
  • Mr. Russell PicketGroup Financial Controller
  • Ms. Karley Charlotte Mouatt CheesmanCompany Secretary
  • Mr. Matthew HeathPrincipal Scientist

Financials

Income Statement

Currency: GBP2002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Total Revenue15.14M17.33M18.00M20.61M23.56M25.74M31.02M37.76M40.75M41.55M41.28M39.28M41.95M43.23M48.51M64.14M68.35M73.72M78.20M84.33M72.77M59.59M55.20M55.04M
Growth (%)-+14.47%+3.88%+14.47%+14.33%+9.27%+20.51%+21.71%+7.93%+1.97%-0.65%-4.85%+6.81%+3.04%+12.21%+32.22%+6.56%+7.86%+6.09%+7.83%-13.71%-18.11%-7.36%-0.28%
Cost of Revenue5.27M5.33M5.51M4.85M6.51M10.07M10.87M13.56M11.16M13.22M13.67M11.95M11.95M12.18M14.07M16.77M17.01M18.38M20.69M22.53M23.81M26.90M25.46M29.91M
Gross Profit9.87M12.00M12.49M15.75M17.05M15.67M20.16M24.19M29.59M28.33M27.61M27.33M30.00M31.05M34.44M47.37M51.33M55.34M57.51M61.80M48.95M32.69M29.74M25.13M
Gross Margin65.18%69.26%69.37%76.45%72.35%60.89%64.98%64.08%72.60%68.18%66.88%69.57%71.51%71.83%71.00%73.85%75.11%75.07%73.54%73.28%67.27%54.86%53.87%45.65%
Operating Expense5.62M13.57M10.93M13.34M10.33M-10.60M4.56M19.09M28.13M28.22M26.52M26.66M29.00M30.31M46.56M49.35M58.04M57.17M53.06M57.77M61.95M67.54M64.99M54.63M
Operating Income4.25M-1.57M1.56M2.42M6.71M26.27M15.59M5.10M1.46M115.00K1.09M668.00K1.00M739.00K-12.12M-1.98M-6.70M-1.84M4.46M4.03M-13.00M-34.85M-35.26M-29.50M
Operating Margin28.08%-9.04%8.64%11.73%28.50%102.07%50.26%13.52%3.57%0.28%2.65%1.70%2.39%1.71%-24.99%-3.09%-9.81%-2.49%5.70%4.78%-17.87%-58.49%-63.87%-53.60%
EBITDA-2.31M5.24M2.27M-1.00M-5.05M-24.67M-17.24M-7.05M2.91M728.00K3.99M2.08M2.12M1.88M-10.11M-291.00K-4.56M5.80M11.69M7.61M-8.69M-36.24M-30.74M-29.43M
EBITDA Margin-15.25%30.26%12.60%-4.87%-21.44%-95.85%-55.58%-18.68%7.13%1.75%9.67%5.30%5.06%4.35%-20.83%-0.45%-6.67%7.87%14.95%9.02%-11.94%-60.82%-55.69%-53.46%
Net Income-4.66M5.18M1.22M-2.19M-6.17M-23.26M-20.30M-11.76M586.00K-2.66M823.00K536.00K741.00K108.00K-13.07M-2.48M-7.53M3.47M7.06M2.89M-13.78M-43.07M-40.22M-40.13M
Net Income Margin-30.80%29.87%6.77%-10.63%-26.20%-90.34%-65.43%-31.16%1.44%-6.41%1.99%1.36%1.77%0.25%-26.95%-3.87%-11.02%4.70%9.03%3.42%-18.93%-72.28%-72.86%-72.91%
R&D2.54M527.00K451.00K5.62M9.56M25.34M16.30M5.30M2.21M1.67M2.10M2.54M2.96M3.12M16.22M9.30M16.02M6.95M9.00M12.89M15.66M20.12M22.90M15.38M
R&D as % of Total Revenue16.79%3.04%2.51%27.27%40.58%98.45%52.54%14.03%5.42%4.02%5.08%6.45%7.06%7.22%33.44%14.49%23.44%9.43%11.51%15.28%21.52%33.77%41.49%27.94%
Interest Expense545.00K39.00K26.00K42.00K4.00K131.00K1.97M3.24M1.79M1.54M457.00K404.00K308.00K218.00K122.00K71.00K122.00K11.00K339.00K386.00K541.00K2.44M3.88M6.84M
Interest Expense % of Total Revenue3.60%0.23%0.14%0.20%0.02%0.51%6.36%8.57%4.39%3.70%1.11%1.03%0.73%0.50%0.25%0.11%0.18%0.01%0.43%0.46%0.74%4.10%7.02%12.43%

Balance Sheet

Currency: GBP2002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Total Assets9.68M11.15M11.23M26.66M37.88M23.99M23.18M22.08M29.11M30.62M27.75M28.96M28.40M50.70M56.68M57.18M51.02M68.50M86.22M88.09M72.95M66.77M64.83M67.54M
Total Liabilities14.07M5.60M4.16M6.58M5.18M15.40M34.47M45.25M25.23M28.48M13.16M14.29M13.32M16.23M26.36M27.22M27.98M30.94M42.44M39.55M35.18M64.70M61.12M95.74M
Total Equity-6.46M5.55M7.08M20.08M32.70M8.60M-11.29M-23.18M3.89M2.14M14.59M14.67M15.07M34.47M30.32M29.96M23.03M37.56M43.78M48.53M37.77M2.07M3.71M-28.19M
Cash56.00K1.27M1.46M15.08M23.86M5.70M2.30M-4.52M1.05M903.00K1.26M2.03M21.20M23.41M22.12M15.53M27.44M36.96M40.27M20.52M14.85M12.91M12.79M
Total Debt9.01M2.10M1.16M455.00K-2.16M25.84M30.91M11.71M15.15M1.52M288.00K49.00K1.68M3.37M3.33M3.06M2.44M12.18M11.17M10.53M35.99M30.99M60.09M
Net Debt8.95M838.00K-298.00K-14.63M-23.86M-3.54M23.54M30.91M7.18M14.11M620.00K-969.00K-1.98M-19.52M-20.04M-18.80M-12.47M-25.00M-24.78M-29.10M-9.99M21.14M18.07M47.50M

Cash Flow

Currency: GBP2002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Operating Cash Flow-2.01M2.10M1.91M-57.00K-8.10M-18.88M-19.32M-440.00K1.70M-2.03M2.88M2.43M2.17M3.12M-11.84M178.00K-3.80M5.60M12.28M8.52M-14.11M-30.92M-32.14M-28.72M
Investing Cash Flow-328.00K-568.00K-760.00K-372.00K-1.65M-2.65M-2.68M-1.99M-2.01M-2.29M-1.57M-1.16M-1.13M-2.67M-1.49M-1.94M-2.50M-3.35M-2.77M-2.76M-3.06M-4.67M-1.20M-3.15M
Financing Cash Flow2.07M-316.00K-648.00K14.05M18.53M3.37M18.60M103.00K4.89M764.00K-2.73M148.00K20.08M20.08M12.54M-188.00K-294.00K9.54M-110.00K-2.03M-2.64M29.91M31.43M32.04M
Capital Expenditure328.00K406.00K760.00K903.00K2.19M3.11M2.62M1.72M1.70M1.24M1.26M821.00K898.00K1.09M1.23M1.50M2.00M2.81M2.55M2.56M3.06M4.67M3.40M3.26M
Free Cash Flow-2.34M1.69M1.15M-960.00K-10.29M-21.99M-21.95M-2.16M4.00K-3.26M1.62M1.61M1.27M2.03M-13.07M-1.32M-5.81M2.79M9.73M5.95M-17.17M-35.59M-35.54M-31.98M
FCF to OCF116.33%80.62%60.13%1684.21%127.05%116.47%113.58%491.14%0.24%161.03%56.22%66.24%58.67%65.07%110.41%-742.70%152.74%49.82%79.25%69.92%121.66%115.10%110.58%111.37%

Earnings

Report DateMar 24, 2014Sep 22, 2014Mar 2, 2015Sep 22, 2015Mar 8, 2016Sep 26, 2016Mar 6, 2017Sep 28, 2017Mar 7, 2018Sep 26, 2018Mar 6, 2019Sep 25, 2019Mar 4, 2020Sep 23, 2020Mar 1, 2021Sep 23, 2021Mar 3, 2022Sep 29, 2022Mar 31, 2025Sep 30, 2025Dec 11, 2025
EPS Estimate0.000.000.000.000.000.000.000.00-0.000.00-1.410.00-0.00---2.000.000.000.00
EPS Actual0.000.000.000.000.00-0.020.01-0.020.01-0.020.02-0.010.02-0.010.02-0.020.01-0.030.000.00-0.01
Surprise-----------99.29%-----98.50%---
Timing----------------Pre-marketAfter-hours---

Key Statistics & Ratios

Market Cap300.80M
Enterprise Value317.46M
Trailing P/E0.00
Forward P/E106.38
PEG Ratio0.00
Price / Sales5.25
Price / Book70.79
EPS-0.01
Book Value0.001
Revenue (TTM)57.29M
Gross Profit (TTM)29.92M
EBITDA-31.61M
Profit Margin-84.08%
Operating Margin-31.35%
Return on Equity-369.20%
Return on Assets-29.64%
Shares Outstanding6.33B
Shares Float701.97M
Beta0.83
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%